Preliminary Study on Clinical Characteristics and Pathogenesis of IQSEC2 Mutations Patients
Yun Ren,Xiaona Luo,Haiyan Tong,Simei Wang,Jinbin Yan,Longlong Lin,Yucai Chen
DOI: https://doi.org/10.2147/pgpm.s455840
2024-05-30
Pharmacogenomics and Personalized Medicine
Abstract:Yun Ren, &ast Xiaona Luo, &ast Haiyan Tong, Simei Wang, Jinbin Yan, Longlong Lin, Yucai Chen Department of Neurology, Shanghai Children's Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yucai Chen, Email Background: The IQ motif and Sec7 domain ArfGEF 2 ( IQSEC2 ), an X-linked gene that encodes the BRAG1 protein, is a guanine nucleotide exchange factor for the ADP ribosylation factor (ARF) protein family in the small guanosine triphosphate (GTP) binding protein. Mutations in this gene result in disorders such as intellectual disability (ID) and epilepsy. In this study, we analyze the clinical features of two patients with IQSEC2 -mutation-related disease and discuss their possible pathogenesis. Methods: The two patients were diagnosed with ID and epilepsy. Genetic testing was performed using whole-exome sequencing, and the three-dimensional protein structure was analyzed. UCSC Genome Browser was used to analyze the conservation of IQSEC2 in different species. We compared IQSEC2 expression in the proband families with that in a control group, as well as the expression of the postsynaptic identity protein 95 (PSD-95), synapse-associated protein 97 (SAP97), ADP ribosylation factor 6 (ARF-6), and insulin receptor substrate 53kDa ( IRSP53 ) genes interacting with IQSEC2 . Results: We identified two semi-zygote mutations located in conserved positions in different species: an unreported de novo mutation, C.3576C>A (p. Tyr1192&ast), and a known mutation, c.2983C>T (p. Arg995Trp). IQSEC2 mutations resulted in significant changes in the predicted three-dimensional protein structure, while its expression in the two probands was significantly lower than that in the age-matched control group, and IQSEC2 expression in proband 1 was lower than that in his family members. The expression levels of PSD-95, ARF-6 , and SAP97, IRSP 53 , which interact with IQSEC2 , were also significantly different from those in the family members and age-matched healthy children. Conclusion: The clinical phenotype resulting from IQSEC2 mutations can be explained by the significant decrease in its expression, loss of function of the mutant protein, and change in the expression of related genes. Our results provide novel insights into the molecular phenotype conferred by the IQSEC2 variants. Keywords: IQSEC2 , expression level, intellectual disability, infantile spasm, related genes IQSEC2 (NCBI Reference Sequence: NM_001111125.3), located on chromosome Xp11.22, is 6011 bp in size. The transcript contains 15 exons, and BRAG1, the encoded protein, contains 1488 amino acids. IQSEC2 is named according to its two conserved regions: IQ (347–376) and the SEC7 domain (746–939). The IQ consists of approximately 30 isoleucine and glutamine amino acids and constitutes the initial domain of the IQSEC2 protein and confers calmodulin-binding ability. The SEC7 domain contains approximately 200 amino acids and is responsible for the guanine nucleotide exchange function (GEF). Other functional structures of IQSEC2 include an N-terminal coiled-coil (CC) domain (23–74), a specific PH domain (951–1085) that binds to inositol phosphate alone, and two C-terminal binding motifs that are crucial in the cell scaffold structure. A proline-rich motif (PRM) (1424–1434) and a PDZ-binding motif (1484–1488) are also present. The PDZ-binding motif is named after the initials of three homologous proteins, namely, postsynaptic density protein 95 (PSD-95), Drosophila disc large tumor suppressor ( DLG1 ), and zonula occludens-1 protein (ZO-1). 1 IQSEC2 interacts with postsynaptic density protein 95 (PSD-95) through its C-terminal PDZ binding domain, forming a complex with N-methyl-D-aspartate ( NMDA ) receptor and allowing for Ca 2+ influx, which in turn binds to the IQ domain of IQSEC2 , thereby inducing a conformational change that activates its catalytic domain SEC7. IQSEC2 acts as a guanine nucleotide exchange factor (GEF) for ADP ribosylation factors (ARFs) through its Sec7 domain, promoting GTP exchange for GDP on ADP ribosylation factor 6 (ARF6) and activating it. The activated ARF6 then promotes the downregulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors through the stress-activated protein kinase JNK. 1,2 Therefore, IQSEC2 regulates the membrane structure and synaptic function of neurons. In addition, IQSEC2 plays an important role in regu -Abstract Truncated-
pharmacology & pharmacy